TRUE Private Wealth Advisors bought a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 17,410 shares of the biotechnology company’s stock, valued at approximately $314,000.

Other large investors have also recently added to or reduced their stakes in the company. California Public Employees Retirement System increased its stake in Corcept Therapeutics by 3.6% in the 2nd quarter. California Public Employees Retirement System now owns 148,200 shares of the biotechnology company’s stock worth $1,749,000 after purchasing an additional 5,200 shares in the last quarter. Rhumbline Advisers increased its stake in Corcept Therapeutics by 21.5% in the 2nd quarter. Rhumbline Advisers now owns 87,672 shares of the biotechnology company’s stock worth $1,035,000 after purchasing an additional 15,494 shares in the last quarter. Shaker Investments LLC OH purchased a new position in Corcept Therapeutics in the 3rd quarter worth about $2,202,000. Sei Investments Co. increased its stake in Corcept Therapeutics by 344.8% in the 3rd quarter. Sei Investments Co. now owns 17,562 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 13,614 shares in the last quarter. Finally, Voya Investment Management LLC increased its stake in Corcept Therapeutics by 46.2% in the 2nd quarter. Voya Investment Management LLC now owns 41,598 shares of the biotechnology company’s stock worth $491,000 after purchasing an additional 13,145 shares in the last quarter. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

In other Corcept Therapeutics news, Director G Leonard Baker, Jr. sold 30,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $17.59, for a total transaction of $527,700.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Robert S. Fishman sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $16.72, for a total value of $133,760.00. Following the sale, the insider now owns 8,000 shares of the company’s stock, valued at $133,760. The disclosure for this sale can be found here. Insiders have sold a total of 46,000 shares of company stock valued at $810,820 over the last 90 days. Corporate insiders own 19.20% of the company’s stock.

A number of equities analysts recently weighed in on CORT shares. Zacks Investment Research cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Piper Jaffray Companies reissued a “buy” rating and issued a $24.00 price target on shares of Corcept Therapeutics in a research note on Wednesday, October 11th. Finally, BidaskClub cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $21.00.

Corcept Therapeutics Incorporated (CORT) opened at $23.98 on Friday. The firm has a market capitalization of $2,691.05, a PE ratio of 82.69 and a beta of 1.89. Corcept Therapeutics Incorporated has a 12 month low of $6.70 and a 12 month high of $24.02.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported $0.11 EPS for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02). Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. The business had revenue of $42.70 million for the quarter, compared to analyst estimates of $41.64 million. During the same quarter in the previous year, the business posted $0.02 earnings per share. The company’s revenue was up 96.8% compared to the same quarter last year. sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 0.47 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2018/01/20/true-private-wealth-advisors-buys-new-holdings-in-corcept-therapeutics-incorporated-cort.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.